PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL® (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL. SPRYCEL is a prescription medicine used to treat adults who have CML and are not benefitting from, or cannot tolerate, prior treatment including Gleevec®* (imatinib mesylate). The program helps patients learn more about SPRYCEL and how to be involved in treatment decisions with a healthcare provider.
